Genetix Biotherapeutics

BLUE · NASDAQ

Price unavailable right now.

No price history for this range.

BLUE analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Mar 6, 2025

Bull case

bluebird bio Inc. is emphasizing its commitment to developing potentially curative gene therapies for severe genetic diseases, including sickle cell disease and beta-thalassemia, which may lead to significant value creation and cost reduction in healthcare. The company's alignment with ESG principles suggests a strategic focus on sustainable finance, positioning bluebird bio favorably for long-term growth in the biotechnology sector. Despite currently negative gross margins, there is potential for improvement as sales increase, particularly for treatments like SCD, which have lower cost of goods sold, indicating potential future profitability.

Bear case

bluebird bio Inc. has experienced a significant revenue decline, reporting total product revenue of $16.1 million in Q2 2024, which raises concerns about the sustainability of Zynteglo's adoption nearly two years post-launch. The company faces negative gross margins and lacks clarity on how manufacturing costs might improve with future sales, indicating potential financial distress. Additionally, the persistent net losses, amounting to $61 million in the latest quarter, alongside a missed revenue consensus, suggest challenges in achieving profitable operations in the near term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.